Delays Plague Breast and Ovarian Cancer Research

Regulations Slow New Drugs Targeting BRCA Mutations

By Karen Iris Tucker

Published August 14, 2012, issue of August 17, 2012.
  • Print
  • Share Share
  • Single Page

Regulatory hurdles, along with dosing problems, have come to plague a new class of cancer drugs that showed highly encouraging results in early research. Those obstacles have frustrated breast and ovarian cancer patients who are carriers of cancer-causing mutations, particularly prevalent among Ashkenazi Jews, and for whom it was hoped the medicines would prove especially helpful.

Sue Friedman: The founder of FORCE speaks at its annual meeting supporting those with BRCA mutations.
Courtesy Sue Friedman
Sue Friedman: The founder of FORCE speaks at its annual meeting supporting those with BRCA mutations.

Last December, patients eagerly anticipating the completion of trials and FDA approval of Olaparib — then the farthest along in research involving a novel class of therapies called “PARP inhibitors” — were dealt a blow when maker AstraZeneca announced it was, for the time being, discontinuing its late-stage Phase III trial of the drug on patients with serous ovarian cancer, the most common form.

The pharmaceutical company said that Olaparib’s previously reported impressive ability to halt progression of the disease for a time, with limited side effects, would not likely translate into “overall survival benefit,” or the length of time patients live after starting the drug.

No PARP inhibitors are currently in large-scale Phase III trials — the last stage of testing before a company can win FDA approval. But multiple Phase I and II trials are underway. Some early trials indicated that the drugs might prove particularly effective in patients with the inherited BRCA1 or BRCA2 genetic mutations involved in 5% to 10% of all breast and ovarian cancers. With about a one-in-40 chance of carrying a BRCA mutation, Ashkenazi Jews are at higher risk for those diseases compared with those in the general population, where about one in 500 carry a BRCA mutation.

Some academics view the delays in PARP trials as reflective of a contentious change in regulatory policy, regarding how new drugs are evaluated. Dr. Mary Daly, who chairs the department of clinical genetics at Fox Chase Cancer Center in Philadelphia, said: “The move is to thinking that it is not enough to put off progression with a drug, but that the drug has to actually extend life. It’s still somewhat controversial, because some argue that prolonging progression-free survival is valuable in itself.”

Olaparib researchers also reported difficulty in identifying a suitable tablet dose for use in a Phase III trial. AstraZeneca is currently reformulating Olaparib into higher-dose capsules, but the process may significantly delay completion of the clinical trial.

Other PARP inhibitors face similar problems.


The Jewish Daily Forward welcomes reader comments in order to promote thoughtful discussion on issues of importance to the Jewish community. In the interest of maintaining a civil forum, The Jewish Daily Forwardrequires that all commenters be appropriately respectful toward our writers, other commenters and the subjects of the articles. Vigorous debate and reasoned critique are welcome; name-calling and personal invective are not. While we generally do not seek to edit or actively moderate comments, our spam filter prevents most links and certain key words from being posted and The Jewish Daily Forward reserves the right to remove comments for any reason.





Find us on Facebook!
  • It’s over. The tyranny of the straight-haired, button nosed, tan-skinned girl has ended. Jewesses rejoice!
  • It's really, really, really hard to get kicked out of Hebrew school these days.
  • "If Netanyahu re-opens the settlement floodgates, he will recklessly bolster the argument of Hamas that the only language Israel understands is violence."
  • Would an ultra-Orthodox leader do a better job of running the Met Council?
  • So, who won the war — Israel or Hamas?
  • 300 Holocaust survivors spoke out against Israel. Did they play right into Hitler's hands?
  • Ari Folman's new movie 'The Congress' is a brilliant spectacle, an exhilarating visual extravaganza and a slapdash thought experiment. It's also unlike anything Forward critic Ezra Glinter has ever seen. http://jd.fo/d4unE
  • The eggplant is beloved in Israel. So why do Americans keep giving it a bad rap? With this new recipe, Vered Guttman sets out to defend the honor of her favorite vegetable.
  • “KlezKamp has always been a crazy quilt of gay and straight, religious and nonreligious, Jewish and gentile.” Why is the klezmer festival shutting down now?
  • “You can plagiarize the Bible, can’t you?” Jill Sobule says when asked how she went about writing the lyrics for a new 'Yentl' adaptation. “A couple of the songs I completely stole." Share this with the theater-lovers in your life!
  • Will Americans who served in the Israeli army during the Gaza operation face war crimes charges when they get back home?
  • Talk about a fashion faux pas. What was Zara thinking with the concentration camp look?
  • “The Black community was resistant to the Jewish community coming into the neighborhood — at first.” Watch this video about how a group of gardeners is rebuilding trust between African-Americans and Jews in Detroit.
  • "I am a Jewish woman married to a non-Jewish man who was raised Catholic, but now considers himself a “common-law Jew.” We are raising our two young children as Jews. My husband's parents are still semi-practicing Catholics. When we go over to either of their homes, they bow their heads, often hold hands, and say grace before meals. This is an especially awkward time for me, as I'm uncomfortable participating in a non-Jewish religious ritual, but don't want his family to think I'm ungrateful. It's becoming especially vexing to me now that my oldest son is 7. What's the best way to handle this situation?" http://jd.fo/b4ucX What would you do?
  • Maybe he was trying to give her a "schtickle of fluoride"...
  • from-cache

Would you like to receive updates about new stories?




















We will not share your e-mail address or other personal information.

Already subscribed? Manage your subscription.